Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature

IRÈNE ASMANE, VALÈRE LITIQUE, STEVE HEYMANN, LUC MARCELLIN, ANNE-CÉCILE MÉTIVIER, BRIGITTE DUCLOS, JEAN-PIERRE BERGERAT and JEAN-EMMANUEL KURTZ
Anticancer Research September 2008, 28 (5B) 3041-3045;
IRÈNE ASMANE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VALÈRE LITIQUE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEVE HEYMANN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUC MARCELLIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNE-CÉCILE MÉTIVIER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRIGITTE DUCLOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEAN-PIERRE BERGERAT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEAN-EMMANUEL KURTZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j-emmanuel.kurtz@chru-strasbourg.fr
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. The outcome of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered. Chemotherapy, generally consisting of the combination of anthracyclines and ifosfamide, has little, but consistent effect. We report three cases of angiosarcoma in which first-line chemotherapy with adriamycin 40 mg/m2 day 1, ifosfamide 3 g/m2 day 1-2, cisplatin 35 mg/m2 day 1-2 and paclitaxel 175 mg/m2 day 3 led to clinically meaningful responses. The clinical relevance of incorporating paclitaxel in conventional soft tissue chemotherapy schedules in the light of both literature data and our experience is discussed. We emphasize the need for designing trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs.

  • Polychemotherapy
  • angiosarcoma
  • first-line

Footnotes

  • Received February 7, 2008.
  • Revision received June 4, 2008.
  • Accepted June 18, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (5B)
Anticancer Research
Vol. 28, Issue 5B
September-October 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature
IRÈNE ASMANE, VALÈRE LITIQUE, STEVE HEYMANN, LUC MARCELLIN, ANNE-CÉCILE MÉTIVIER, BRIGITTE DUCLOS, JEAN-PIERRE BERGERAT, JEAN-EMMANUEL KURTZ
Anticancer Research Sep 2008, 28 (5B) 3041-3045;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature
IRÈNE ASMANE, VALÈRE LITIQUE, STEVE HEYMANN, LUC MARCELLIN, ANNE-CÉCILE MÉTIVIER, BRIGITTE DUCLOS, JEAN-PIERRE BERGERAT, JEAN-EMMANUEL KURTZ
Anticancer Research Sep 2008, 28 (5B) 3041-3045;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Epithelioid Angiosarcoma of the Scapula
  • Google Scholar

More in this TOC Section

  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire